Combined blockade of angiotensin II type 1 receptor and activation of peroxisome proliferator-activated receptor-γ by telmisartan effectively inhibits vascularization and growth of murine endometriosis-like lesions

Human Reproduction

Volumn 29, Issue 5, 2014, Pages 1011-1024

  Nenicu, A ^a   Korbel C ^a   Gu, Y ^a   Menger, M D ^a   Laschke, M W ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

angiogenesis; angiotensin receptor; endometriosis; PPAR ; telmisartan

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; CD31 ANTIGEN; DIMETHYL SULFOXIDE; KI 67 ANTIGEN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; R 2408; T 8949; TELMISARTAN; UNCLASSIFIED DRUG; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BENZIMIDAZOLE DERIVATIVE; BENZOIC ACID DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; ARTICLE; CAPILLARY DENSITY; CLINICAL FEATURE; CONTROLLED STUDY; DRUG ACTIVATION; DRUG EFFICACY; DRUG MEGADOSE; ENDOMETRIOSIS; ENZYME ACTIVATION; FEMALE; FLUORESCENCE MICROSCOPY; GENE EXPRESSION PROFILING; HISTOPATHOLOGY; IMMUNOCOMPETENT CELL; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; INTRAVITAL FLUORESCENCE MICROSCOPY; MICROVASCULARIZATION; MOUSE; MURINE MODEL; NONHUMAN; NUCLEOTIDE SEQUENCE; PERITONEAL CAVITY; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; UNINDEXED SEQUENCE; VASCULAR RING; AGONISTS; ANIMAL; DISEASE MODEL; DOWN REGULATION; GENETICS; NEOVASCULARIZATION, PATHOLOGIC; PERITONEAL DISEASES; UPREGULATION;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BENZIMIDAZOLES; BENZOATES; DISEASE MODELS, ANIMAL; DOWN-REGULATION; ENDOMETRIOSIS; FEMALE; GENE EXPRESSION PROFILING; MICE; NEOVASCULARIZATION, PATHOLOGIC; PERITONEAL DISEASES; PPAR GAMMA; THIAZOLIDINEDIONES; UP-REGULATION;

EID: 84898855089     PISSN: 02681161     EISSN: 14602350     Source Type: Journal    
DOI: 10.1093/humrep/deu035     Document Type: Article

References (55)

1. Aljada A, O'Connor L, Fu YY, Mousa SA. PPAR gamma ligands, rosiglitazone and pioglitazone, inhibit bFGF-and VEGF-mediated angiogenesis. Angiogenesis 2008;11:361-367.
2. Asante A, Taylor RN. Endometriosis: the roleofneuroangiogenesis. Annu Rev Physiol 2011;73:163-182.
3. Auerbach R, Lewis R, Shinners B, Kubai L, Akhtar N. Angiogenesis assays: a critical overview. Clin Chem 2003;49:32-40.
4. Augoulea A, Alexandrou A, Creatsa M, Vrachnis N, Lambrinoudaki I. Pathogenesis of endometriosis: the role of genetics, inflammation and oxidative stress. Arch Gynecol Obstet 2012;286:99-103.
5. Aytan H, Caliskan AC, Demirturk F, Aytan P, Koseoglu DR. Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone reduces the size of experimental endometriosis in the rat model. Aust N Z J Obstet Gynaecol 2007;47:321-325.
6. Berger A, Stierkorb E, Nickenig G. The role oftheAUUUUA hexamerfor the posttranscriptional regulation of the AT1 receptor mRNA stability. Biochem Biophys Res Commun 2005;330:805-812.
7. Bergqvist A, Bruse C, Carlberg M, Carlström K. Interleukin 1beta, interleukin-6, and tumor necrosis factor-alpha in endometriotic tissue and in endometrium. Fertil Steril 2001;75:489-495.
8. Braileanu GT, Simasko SM, Speth RC, Daubert D, Hu J, Mirando MA. Angiotensin II increases intracellular calcium concentration in pig endometrial stromal cells through type 1 angiotensin receptors, but does not stimulate phospholipase C activity or prostaglandin F2alpha secretion. Reprod Fertil Dev 2002;14:199-205.
9. Buchweitz O, Staebler A, Wülfing P, Hauzman E, Greb R, Kiesel L. COX-2 overexpression in peritoneal lesions is correlated with nonmenstrual chronic pelvic pain. Eur J Obstet Gynecol Reprod Biol 2006;124:216-221.
10. Burney RO, Giudice LC. Pathogenesis and pathophysiology of endometriosis. Fertil Steril 2012;98:511-519.
11. Carbajo-Lozoya J, Lutz S, Feng Y, Kroll J, Hammes HP, Wieland T. Angiotensin II modulates VEGF-driven angiogenesis by opposing effects of type 1 and type 2 receptor stimulation in the microvascular endothelium. Cell Signal 2012;24:1261-1269.
12. Demirturk F, Aytan H, Caliskan AC, Aytan P, Koseoglu DR. Effect of peroxisome proliferator-activated receptor-gamma agonist rosiglitazone on the induction of endometriosis in an experimental rat model. J Soc Gynecol Investig 2006;13:58-62.
13. Desouza CV, Rentschler L, Fonseca V. Peroxisome proliferator-activated receptors as stimulants of angiogenesis in cardiovascular disease and diabetes. Diabetes Metab Syndr Obes 2009;2:165-172.
14. Ehrmantraut S, Laschke MW, Merkel D, Scheuer C, Willnecker V, Meyer-Lindenberg A, Menger MD, Naumann A. Perioperative steroid administration inhibits angiogenic host tissue response to porous polyethylene (Medpor) implants. Eur Cell Mater 2010;19:107-116.
15. Feng D, Welker S, Körbel C, Rudzitis-Auth J, Menger MD, Montenarh M, Laschke MW. Protein kinase CK2 is a regulator of angiogenesis in endometriotic lesions. Angiogenesis 2012;15:243-252.
16. Galle PC. Clinical presentation and diagnosis of endometriosis. Obstet Gynecol Clin North Am 1989;16:29-42.
17. Gupta S, Agarwal A, Krajcir N, Alvarez JG. Role of oxidative stress in endometriosis. Reprod Biomed Online 2006;13:126-134.
18. Herington JL, Crispens MA, Carvalho-Macedo AC, Camargos AF, Lebovic DI, Bruner-Tran KL, Osteen KG. Development and prevention of postsurgical adhesions in a chimeric mouse model of experimental endometriosis. Fertil Steril 2011;95:1295-1301.
19. Hudelist G, Fritzer N, Thomas A, Niehues C, Oppelt P, Haas D, Tammaa A, Salzer H. Diagnostic delay for endometriosis in Austria and Germany: causes and possible consequences. Hum Reprod 2012;27:3412-3416.
20. Kliewer SA, Forman BM, Blumberg B, Ong ES, Borgmeyer U, Mangelsdorf DJ, Umesono K, Evans RM. Differential expression and activationof a family of murine peroxisome proliferator-activated receptors. Proc Natl Acad Sci USA 1994;91:7355-7359.
21. Körbel C, Menger MD, Laschke MW. Size and spatial orientation of uterine tissue transplants on the peritoneum crucially determine the growth and cyst formation of endometriosis-like lesions in mice. Hum Reprod 2010; 25:2551-2558.
22. Laschke MW, Menger MD. In vitro and in vivo approaches to study angiogenesis in the pathophysiology and therapy of endometriosis. Hum Reprod Update 2007;13:331-342.
23. Laschke MW, Menger MD. Anti-angiogenic treatment strategies for the therapy of endometriosis. Hum Reprod Update 2012;18:682-702.
24. Laschke MW, Elitzsch A, Vollmar B, Menger MD. In vivo analysis of angiogenesis in endometriosis-like lesions by intravital fluorescence microscopy. Fertil Steril 2005;84 Suppl 2:1199-1209.
25. Laschke MW, Elitzsch A, Scheuer C, Vollmar B, Menger MD. Selective cyclo-oxygenase-2 inhibition induces regression of autologous endometrial grafts by down-regulation of vascular endothelial growth factor-mediated angiogenesis and stimulation of caspase-3-dependent apoptosis. Fertil Steril 2007;87:163-171.
26. Laschke MW, Körbel C, Rudzitis-Auth J, Gashaw I, Reinhardt M, Hauff P, Zollner TM, Menger MD. High-resolution ultrasound imaging: a novel technique for the noninvasive in vivo analysis of endometriotic lesion and cyst formation insmall animal models. Am JPathol 2010;176:585-593.
27. Laschke MW, Giebels C, Menger MD. Vasculogenesis: a new piece of the endometriosis puzzle. Hum Reprod Update 2011a;17:628-636.
28. Laschke MW, Vollmar B, Menger MD. The dorsal skinfold chamber: window into the dynamic interaction of biomaterials with their surrounding host tissue. Eur Cell Mater 2011b;22:147-164.
29. Laschke MW, Vorstermanvan Oijen AE, Scheuer C, Menger MD. Invitroand in vivo evaluation of the anti-angiogenic actions of 4-hydroxybenzyl alcohol. Br J Pharmacol 2011c;163:835-844.
30. Lebovic DI, Kir M, Casey CL. Peroxisome proliferator-activated receptor-gamma induces regression of endometrial explants in a rat model of endometriosis. Fertil Steril 2004;82 Suppl 3:1008-1013.
31. Lebovic DI, Mwenda JM, Chai DC, Mueller MD, Santi A, Fisseha S, D'Hooghe T. PPAR-gamma receptor ligand induces regression of endometrial explants in baboons: a prospective, randomized, placebo-and drug-controlled study. Fertil Steril 2007;88:1108-1119.
32. Lebovic DI, Mwenda JM, Chai DC, Santi A, Xu X, D'Hooghe T. Peroxisome proliferator-activated receptor-(gamma) receptor ligand partially prevents the development of endometrial explants in baboons: a prospective, randomized, placebo-controlled study. Endocrinology 2010; 151:1846-1852.
33. Lousse JC, Van Langendonckt A, Defrere S, Ramos RG, Colette S, Donnez J. Peritoneal endometriosis is an inflammatory disease. Front Biosci (Elite Ed) 2012;4:23-40.
34. Machado DE, Berardo PT, Landgraf RG, Fernandes PD, Palmero C, Alves LM, Abrao MS, Nasciutti LE. Aselective cyclooxygenase-2 inhibitor suppresses the growth of endometriosis with an antiangiogenic effect in a rat model. Fertil Steril 2010;93:2674-2679.
35. Mac Kenzie A. Endothelium-derived vasoactive agents, AT1 receptors and inflammation. Pharmacol Ther 2011;131:187-203.
36. Nagai N, Oike Y, Izumi-Nagai K, Urano T, Kubota Y, Noda K, Ozawa Y, Inoue M, Tsubota K, Suda T et al. Angiotensin II type 1 receptor-mediated inflammation is required for choroidal neovascularization. Arterioscler Thromb Vasc Biol 2006;26:2252-2259.
37. Ohama Y, Harada T, Iwabe T, Taniguchi F, Takenaka Y, Terakawa N. Peroxisome proliferator-activated receptor-gamma ligand reduced tumor necrosis factor-alpha-induced interleukin-8 production and growth in endometriotic stromal cells. Fertil Steril 2008;89:311-317.
38. Peeters LL, Vigne JL, Tee MK, Zhao D, Waite LL, Taylor RN. PPAR gamma represses VEGF expression in human endometrial cells: implications for uterine angiogenesis. Angiogenesis 2005;8:373-379.
39. Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEB J 2008;22:659-661.
40. Reis FM, Petraglia F, Taylor RN. Endometriosis: hormone regulation and clinical consequences of chemotaxis and apoptosis. Hum Reprod Update 2013;19:406-418.
41. Rosen ED, Spiegelman BM. PPARgamma: a nuclear regulator of metabolism, differentiation, and cell growth. J Biol Chem 2001;276:37731-37734.
42. Rosenson RS, Wright RS, Farkouh M, Plutzky J. Modulating peroxisome proliferator-activated receptors for therapeutic benefit? Biology, clinical experience, and future prospects. Am Heart J 2012;164:672-680.
43. Rudzitis-Auth J, Körbel C, Scheuer C, Menger MD, Laschke MW. Xanthohumol inhibits growth and vascularization of developing endometriotic lesions. Hum Reprod 2012;27:1735-1744.
44. Rudzitis-Auth J, Menger MD, Laschke MW. Resveratrol is a potent inhibitor of vascularization and cell proliferation in experimental endometriosis. Hum Reprod 2013;28:1339-1347.
45. Sheu WH, Ou HC, Chou FP, Lin TM, Yang CH. Rosiglitazone inhibits endothelial proliferation and angiogenesis. Life Sci 2006;78: 1520-1528.
46. Shindo T, Takasaki K, Uchida K, Onimura R, Kubota K, Uchida N, Irie KKatsurabayashi S, Mishima K, Nishimura R et al. Ameliorative effects of telmisartan on the inflammatory response and impaired spatial memory in a rat model of Alzheimer's disease incorporating additional cerebrovascular disease factors. Biol Pharm Bull 2012;35:2141-2147.
47. Sikora J, Mielczarek-Palacz A, Kondera-Anasz Z. Imbalance in cytokines from interleukin-1 family-role in pathogenesis of endometriosis. Am J Reprod Immunol 2012;68:138-145.
48. Tamaki Y, Nakade Y, Yamauchi T, Makino Y, Yokohama S, Okada M, Aso K, Kanamori H, Ohashi T, Sato K et al. Angiotensin II type 1 receptor antagonist prevents hepatic carcinoma in rats with nonalcoholic steatohepatitis. J Gastroenterol 2013;48:491-503.
49. Taniguchi F, Kaponis A, Izawa M, Kiyama T, Deura I, Ito M, Iwabe T, Adonakis G, Terakawa N, Harada T. Apoptosis and endometriosis. Front Biosci (Elite Ed) 2011;3:648-662.
50. Toyama K, Nakamura T, Kataoka K, Yasuda O, Fukuda M, Tokutomi Y, Dong YF, Ogawa H, Kim-Mitsuyama S. Telmisartan protects against diabetic vascular complications in a mouse model of obesity and type 2 diabetes, partially through peroxisome proliferator activated receptor-g-dependent activity. Biochem Biophys Res Commun 2011; 410:508-513.
51. Tsujimura Y, Matsutani T, Matsuda A, Kutsukake M, Uchida E, Sasajima K, Tamura K. Effects of pioglitazone on survival and omental adipocyte function in mice with sepsis induced by cecal ligation and puncture. J Surg Res 2011;171:e215-e221.
52. Velasco I, Acién P, Campos A, Acién MI, Ruiz-Maciá E. Interleukin-6 and other soluble factors in peritoneal fluid and endometriomas and their relation to pain and aromatase expression. J Reprod Immunol 2010; 84:199-205.
53. Verdecchia P, Angeli F, Gentile G, Mazzotta G, Reboldi G. Telmisartan for the reduction of cardiovascular morbidity and mortality. Expert Rev Clin Pharmacol 2011;4:151-161.
54. Ye Y, Keyes KT, Zhang CF, Perez-Polo JR, Lin Y, Birnbaum Y. Additive effect of TAK-491, a new angiotensin receptor blocker, and pioglitazone, in reducing myocardial infarct size. Cardiovasc Drugs Ther 2010;24:107-120.
55. Zheng Z, Lin S, Shi H. A systematic review and meta-analysis of telmisartan versus valsartan in the management of essential hypertension. J Clin Hypertens (Greenwich) 2010;12:414-421.